High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors

Cancer Research

Volumn 71, Issue 5, 2011, Pages 1999-2009

  Rushworth, Stuart A ^a   Bowles, Kristian M ^b   MacEwan, David J ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; HEME OXYGENASE 1; PROTEASOME INHIBITOR; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; BIOACCUMULATION; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; GENE INACTIVATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; MYELODYSPLASTIC SYNDROME; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BLOTTING, WESTERN; BORONIC ACIDS; CELL NUCLEUS; CELL SEPARATION; CHROMATIN IMMUNOPRECIPITATION; DRUG RESISTANCE, NEOPLASM; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; LEUKEMIA, MYELOID, ACUTE; NF-E2-RELATED FACTOR 2; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79952202823     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3018     Document Type: Article

References (50)

1. The Leukemia and Lymphoma Society. Available from:www.leukemia-lymphoma. org. 2010.
2. Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009;113:4179-87.
3. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106:1154-63. (Pubitemid 41130866)
4. Skaug B, Jiang X, Chen ZJ. The role of ubiquitin in NF-κB regulatory pathways. Annu Rev Biochem 2009;78:769-96.
5. Kobayashi M, Yamamoto M. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal 2005;7:385-94. (Pubitemid 40279806)
6. Lin Y, Bai L, Chen W, Xu S. The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets 2010;14:45-55.
7. Hong YB, Kang HJ, Kwon SY, Kim HJ, Kwon KY, Cho CH, et al. Nuclear factor (erythroid-derived 2)-like 2 regulates drug resistance in pancreatic cancer cells. Pancreas 2010;39:463-72.
8. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, et al. Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001;98:2301-7.
9. Hayes JD, McMahon M. Nrf2 and Keap1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 2009;34:176-88.
10. Bloom DA, Jaiswal AK. Phosphorylation of Nrf2 at Ser(40) by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H:quinone oxidoreductase-1 gene expression. J Biol Chem 2003;278:44675-82.
11. Camhi SL, Alam J, Wiegand GW, Chin BY, Choi AMK. Transcriptional activation of the HO-1 gene by lipopolysaccharide is mediated by 5 ′ distal enhancers: role of reactive oxygen intermediates and AP-1. Am J Respir Cell Mol Biol 1998;18:226-34. (Pubitemid 128355196)
12. Rushworth SA, Bowles KM, Raninga P, MacEwan DJ. NF-κB-inhibited acute myeloid leukemia cells are rescued from apoptosis by heme oxygenase-1 induction. Cancer Res 2010;70:2973-83.
13. Shan Y, Lambrecht RW, Donohue SE, Bonkovsky HL. Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin. FASEB J 2006;20:2651-3.
14. Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res 2008;14:1446-54. (Pubitemid 351413928)
15. Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004;10:3371-6. (Pubitemid 38685442)
16. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005;105:3058-65.
17. Rae C, Langa S, Tucker SJ, MacEwan DJ. Elevated NF-κB responses and FLIP levels in leukemic but not normal lymphocytes: reduction by salicylate allows TNF-induced apoptosis. Proc Natl Acad Sci U S A 2007;104:12790-5. (Pubitemid 47255233)
18. Cordle SR, Donald R, Read MA, Hawiger J. Lipopolysaccharide induces phosphorylation of Mad3 and activation of c-Rel and related NF-κB proteins in human monocytic THP-1 cells. J Biol Chem 1993;268:11803-10. (Pubitemid 23168134)
19. Chi L, Ke Y, Luo C, Gozal D, Liu R. Depletion of reduced glutathione enhances motor neuron degeneration in vitro and in vivo. Neuroscience 2007;144:991-1003. (Pubitemid 46013990)
20. Rushworth SA, MacEwan DJ, O'Connell MA. Lipopolysaccharide-induced expression of NAD(P)H:quinone oxidoreductase 1 and heme oxygenase-1 protects against excessive inflammatory responses in human monocytes. J Immunol 2008;181:6730-7.
21. Yang D, Young K, Kahl B, Markovina S, Miyamoto S. Prevalence of bortezomib-resistant constitutive NF-κB activity in mantle cell lymphoma. Mol Cancer 2008;7:40.
22. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, et al. Phase I trial of the proteasome inhibitor ps-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-7. (Pubitemid 35334752)
23. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, et al. Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells. Blood 2009;114:1046-52.
24. Alam J, Cook JL. How many transcription factors does it take to turn on the heme oxygenase-1 gene?Am J Respir Cell Mol Biol 2007; 36:166-74.
25. Rushworth SA, O'Connell MA. Haem oxygenase-1 in inflammation. Biochem Soc Trans 2004;32:1093-4. (Pubitemid 39655555)
26. Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 2004;24:10941-53. (Pubitemid 39603148)
27. Rushworth SA, MacEwan DJ. HO-1 underlies resistance of AML cells to TNF-induced apoptosis. Blood 2008;111:3793-801.
28. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantlecell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006;107:257-64. (Pubitemid 43053550)
29. Dasmahapatra G, Rahmani M, Dent P, Grant S. The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism. Blood 2006;107:232-40. (Pubitemid 43053548)
30. Du ZX, Zhang HY, Meng X, Guan Y, Wang HQ. Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells. BMC Cancer 2009;9:56.
31. Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A 2002; 99:16220-5. (Pubitemid 35462776)
32. Adams J. Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 2002;14:628-34. (Pubitemid 35387373)
33. Bil J, Winiarska M, Nowis D, Bojarczuk K, Dabrowska-Iwanicka A, Basak GW, et al. Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity. Blood 2010: 115:3745-55.
34. Ishii Y, Itoh K, Morishima Y, Kimura T, Kiwamoto T, Iizuka T, et al. Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced and emphysema. J Immunol 2005;175:6968-75. (Pubitemid 41598943)
35. Rushworth SA, Chen XL, Mackman N, Ogborne RM, O'Connell MA. Lipopolysaccharide-induced heme oxygenase-1 expression in human monocytic cells is mediated via Nrf2 and protein kinase C. J Immunol 2005;175:4408-15. (Pubitemid 41361976)
36. Ogborne RM, Rushworth SA, O'Connell MA. α-Lipoic acid-induced heme oxygenase-1 expression is mediated by nuclear factor erythroid 2-related factor 2 and p38 mitogen-activated protein kinase in human monocytic cells. Arterioscler Thromb Vasc Biol 2005;25:2100-5. (Pubitemid 41416307)
37. Chen XL, Varner SE, Rao AS, Grey JY, Thomas S, Cook CK, et al. Laminar flow induction of antioxidant response element-mediated genes in endothelial cells-a novel anti-inflammatory mechanism. J Biol Chem 2003;278:703-11. (Pubitemid 36790739)
38. Lee JM, Calkins MJ, Chan KM, Kan YW, Johnson JA. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem 2003;278:12029-38. (Pubitemid 36800179)
39. Thimmulappa RK, Lee H, Rangasamy T, Reddy SP, Yamamoto M, Kensler TW, et al. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Inv 2006; 116:984-95.
40. Ogborne RM, Rushworth SA, Charalambos CA, O'Connell MA. Haem oxygenase-1: a target for dietary antioxidants. Biochem Soc Trans 2004;32:1003-5. (Pubitemid 39655527)
41. Rushworth SA, Ogborne RM, Charalambos CA, O'Connell MA. Role of protein kinase C delta in curcumin-induced antioxidant response element-mediated gene expression in human monocytes. Biochem Biophys Res Commun 2006;341:1007-16. (Pubitemid 43221766)
42. Ogborne RM, Rushworth SA, O'Connell MA. Epigallocatechin activates haem oxygenase-1 expression via protein kinase C delta and Nrf2. Biochem Biophys Res Commun 2008;373:584-8.
43. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamato M, Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 2002;62:5196-203. (Pubitemid 35033454)
44. He XQ, Chen MG, Lin GX, Ma Q. Arsenic induces NAD(P)H-quinone oxidoreductase I by disrupting the Nrf2/Keap1/CuI3 complex and recruiting Nrf2/Maf to the antioxidant response element enhancer. J Biol Chem 2006;281:23620-31. (Pubitemid 44274137)
45. Thimmulappa RK, Fuchs RJ, Malhotra D, Scollick C, Traore K, Bream JH, et al. Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils. Antioxid Redox Signaling 2007;9:1963-70. (Pubitemid 47622348)
46. Reichard JF, Sartor MA, Puga A. Bach1 is a specific repressor of HMOX1 that is inactivated by arsenite. J Biol Chem 2008;283: 22363-70.
47. MacLeod AK, McMahon M, Plummer SM, Higgins LG, Penning TM, Igarashi K, et al. Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redoxcycling compounds. Carcinogenesis 2009;30:1571-80.
48. Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 2008;68:1303-9. (Pubitemid 351346836)
49. Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kombairaju P, Bodas M, et al. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther 2010;9:336-46.
50. Hann IM, Stevens RF, Goldstone AH, Rees JK, Wheatley K, Gray RG, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Blood 1997;89:2311-8.